Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin‐Deficient Mice via Upregulation of Angiotensin (1–7)

Abstract

Background Angiotensin II type 1 receptor blockers (ARBs) have been shown to limit the growth of abdominal aortic aneurysm (AAA), but their efficacy is controversial. This study aimed to investigate the molecular mechanism underlying the protective effect of ARBs against AAA progression. Methods and Results Olmesartan, an ARB, was administered to wild‐type and osteoprotegerin ‐knockout ( Opg ‐KO) mice starting 2 weeks before direct application of CaCl 2 to aortas to induce AAA. The protective effect of olmesartan against AAA in wild‐type and Opg ‐KO mice was compared at 6 weeks after AAA induction. Olmesartan prevented AAA progression in Opg ‐KO mice, including excessive aortic dilatation and collapse of tunica media, but not in wild‐type mice. Deficiency of the Opg gene is known to cause excessive activation of the tumor necrosis factor–related apoptosis‐inducing ligand–induced c‐Jun N‐terminal kinase/matrix metalloproteinase 9 pathway, resulting in prolonged AAA progression. Olmesartan attenuated the upregulation of phosphorylated c‐Jun N‐terminal kinase and matrix metalloproteinase 9 expression in the aortic wall of Opg ‐KO mice. In cultured vascular smooth muscle cells, tumor necrosis factor–related apoptosis‐inducing ligand–induced c‐Jun N‐terminal kinase phosphorylation and matrix metalloproteinase 9 expression were inhibited by angiotensin (1–7), the circulating levels of which are increased by ARBs. Furthermore, administering an angiotensin (1–7) antagonist to Opg ‐KO mice diminished the protective effect of olmesartan against AAA progression. Conclusions Olmesartan prevented AAA progression in Opg‐ KO mice by upregulating angiotensin (1–7), suggesting that angiotensin (1–7) may be a key factor that mediates the protective effect of ARBs.